Literature DB >> 25733955

Clinical predictors of therapeutic response to antipsychotics in schizophrenia.

Maren Carbon1, Christoph U Correll2.   

Abstract

The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.

Entities:  

Keywords:  association; marker; predictor; psychosis; remission; response; schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25733955      PMCID: PMC4336920     

Source DB:  PubMed          Journal:  Dialogues Clin Neurosci        ISSN: 1294-8322            Impact factor:   5.986


  161 in total

Review 1.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

2.  Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.

Authors:  Piet Oosthuizen; Robin A Emsley; Mimi C Roberts; Jadri Turner; Linda Keyter; Natasha Keyter; Martijn Torreman
Journal:  Schizophr Res       Date:  2002-12-01       Impact factor: 4.939

Review 3.  Subtyping schizophrenia: implications for genetic research.

Authors:  A Jablensky
Journal:  Mol Psychiatry       Date:  2006-06-27       Impact factor: 15.992

4.  Catamnestic long-term study on the course of life and aging of schizophrenics.

Authors:  L Ciompi
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

5.  Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.

Authors:  Rafael Tabarés-Seisdedos; Vicente Balanzá-Martínez; José Sánchez-Moreno; Anabel Martinez-Aran; José Salazar-Fraile; Gabriel Selva-Vera; Cristina Rubio; Ignacio Mata; Manuel Gómez-Beneyto; Eduard Vieta
Journal:  J Affect Disord       Date:  2008-03-04       Impact factor: 4.839

6.  Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Authors:  Silvana Galderisi; Michael Davidson; René S Kahn; Armida Mucci; Han Boter; Mihai D Gheorghe; Janusz K Rybakowski; Jan Libiger; Sonia Dollfus; Juan J López-Ibor; Joseph Peuskens; Luchezar G Hranov; Wolfgang W Fleischhacker
Journal:  Schizophr Res       Date:  2009-10-12       Impact factor: 4.939

7.  Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.

Authors:  Marie Stentebjerg-Olesen; Pia Jeppesen; Anne K Pagsberg; Anders Fink-Jensen; Sandeep Kapoor; Raja Chekuri; Maren Carbon; Aseel Al-Jadiri; Taishiro Kishimoto; John M Kane; Christoph U Correll
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-11-22       Impact factor: 2.576

8.  Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.

Authors:  Robin Emsley; Petrus P Oosthuizen; Liezl Koen; Dana J H Niehaus; Guadalupe Martinez
Journal:  J Clin Psychiatry       Date:  2012-04       Impact factor: 4.384

Review 9.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

10.  Factors affecting therapeutic compliance: A review from the patient's perspective.

Authors:  Jing Jin; Grant Edward Sklar; Vernon Min Sen Oh; Shu Chuen Li
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

View more
  61 in total

1.  Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project.

Authors:  Roman Kotov; Laura Fochtmann; Kaiqiao Li; Marsha Tanenberg-Karant; Eduardo A Constantino; Joan Rubinstein; Greg Perlman; Eva Velthorst; Anne-Kathrin J Fett; Gabrielle Carlson; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2017-08-04       Impact factor: 18.112

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 3.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

4.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

5.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

6.  Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 7.  Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Authors:  Robin Murray; Christoph U Correll; Gavin P Reynolds; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

8.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

9.  Intrinsic Connectivity of the Globus Pallidus: An Uncharted Marker of Functional Prognosis in People With First-Episode Schizophrenia.

Authors:  Goda Tarcijonas; William Foran; Gretchen L Haas; Beatriz Luna; Deepak K Sarpal
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

Review 10.  Does Gender Influence Outcome in Schizophrenia?

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.